Findings

What do systematic reviews say?

335 questions · 340 findings · 46 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 66 · 19.4%GRADE not reported 16 · 4.7%Very low 102 · 30%Low 68 · 20%Moderate 59 · 17.4%High 29 · 8.5%

Pregabalin 300 mg vs placebo

Withdrawals due to adverse events · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 933 participants
High

Pregabalin 600 mg vs placebo

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 537 participants
Moderate

Pregabalin 600 mg vs placebo

Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 732 participants
Moderate

Gabapentin vs pregabalin

Depression ‐ not reported · patients with chronic kidney disease (CKD) pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg or 600 mg vs placebo

Risk for at least one adverse event per patient · adults with moderate or severe neuropathic pain

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 3697 participants
High

Pregabalin 300 mg or 600 mg vs placebo

Serious AE · adults with moderate or severe neuropathic pain

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 4112 participants
High

Pregabalin vs placebo

Adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo

Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Pregabalin vs placebo at end of treatment

At least 50% reduction in pain · patients with fibromyalgia

Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.59 [1.33, 1.9]
5 studies · 3256 participants
High

Pregabalin vs placebo at end of treatment

Fatigue · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3195 participants
High

Pregabalin vs placebo at end of treatment

Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3139 participants
High

Pregabalin vs placebo at end of treatment

Withdrawals due to adverse events · patients with fibromyalgia

Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.68 [1.36, 2.07]
5 studies · 3259 participants
High

Pregabalin vs placebo at end of treatment

Serious adverse events · patients with fibromyalgia

Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.03 [0.71, 1.49]
4 studies · 2729 participants
Moderate

Pregabalin vs placebo at end of treatment

Dizziness · patients with fibromyalgia

Pregabalin leads to higher dizziness reported to be an adverse event compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 3.77 [3.06, 4.63]
5 studies · 3257 participants
High

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low